within Pharmacolibrary.Drugs.N_NervousSystem.N05A_Antipsychotics.N05AA01_Chlorpromazine;

model Chlorpromazine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.2,
    Cl = 1.9999999999999998e-05,
    adminDuration = 600,
    adminMass = 50 / 1000000,
    adminCount = 1,
    Vd = 0.022,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.00525,
    Tlag = 10.200000000000001,
    Vdp = 0.024,
    k12 = 1.3000000000000001e-05,
    k21 = 1.3000000000000001e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Chlorpromazine</td></tr><tr><td>ATC code:</td><td>N05AA01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>22</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.2</td><td>L/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Chlorpromazine is a typical antipsychotic drug of the phenothiazine class, historically used for the treatment of schizophrenia, psychotic disorders, severe nausea and vomiting, and intractable hiccups. Though still in clinical use in some countries, it has largely been replaced by atypical antipsychotics due to its side effect profile.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Yonkers, KA, et al., &amp; Blumenthal, S (1992). Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. <i>The American journal of psychiatry</i> 149(5) 587–595. DOI:<a href=\"https://doi.org/10.1176/ajp.149.5.587\">10.1176/ajp.149.5.587</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1575248/\">https://pubmed.ncbi.nlm.nih.gov/1575248</a></p></li><li><p>Chetty, M, &amp; Miller, R (2001). Oral contraceptives increase the plasma concentrations of chlorpromazine. <i>Therapeutic drug monitoring</i> 23(5) 556–558. DOI:<a href=\"https://doi.org/10.1097/00007691-200110000-00011\">10.1097/00007691-200110000-00011</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11591904/\">https://pubmed.ncbi.nlm.nih.gov/11591904</a></p></li><li><p>Stephen, LJ (2003). Drug treatment of epilepsy in elderly people: focus on valproic Acid. <i>Drugs &amp; aging</i> 20(2) 141–152. DOI:<a href=\"https://doi.org/10.2165/00002512-200320020-00005\">10.2165/00002512-200320020-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12534314/\">https://pubmed.ncbi.nlm.nih.gov/12534314</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05AA01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Chlorpromazine;
